文献速递神经肿瘤

胶质母细胞瘤的假性进展与真性进展:神经外科医生需要了解的内容

Pseudoprogression versus true progression in glioblastoma: what neurosurgeons need to know.
PubMed 文献 · J Neurosurg · 2023-02-10

本文综述胶质母细胞瘤(GBM)治疗后假性进展(PsP)与真性进展的鉴别要点。PsP指影像上疑似肿瘤进展、实为与治疗反应相关的暂时性改变,可因占位效应和水肿出现新症状。作者介绍神经外科医生识别PsP、辅助手术决策所需的侵入性与非侵入性技术。

要点

  • 胶质母细胞瘤治疗手段不断扩展,影像与临床评估更复杂、更需细致。
  • PsP是与治疗反应相关的暂时性改变,影像上疑似肿瘤进展。
  • 鉴别PsP与真性进展是患者管理与预后的重要决策点。

核心结论

  • 胶质母细胞瘤治疗日益复杂,假性进展的识别对患者管理至关重要,神经外科医生需掌握识别PsP的侵入性与非侵入性技术以辅助手术决策。

研究设计与样本

  • 这是一篇综述,围绕胶质母细胞瘤患者治疗前后影像与临床评估,以及识别假性进展所需的侵入性和非侵入性技术进行阐述。

主要发现

  • 假性进展定义为影像上疑似肿瘤进展、实际为与治疗反应相关的暂时性改变,这些暂时性改变可因占位效应和水肿产生新的临床症状。
  • 假性进展与真性肿瘤进展的鉴别是患者管理和预后的重要决策点。
  • 治疗提供者可选择开始替代治疗、转入临床试验、考虑再次切除或继续当前治疗以期缓解。

临床怎么用

  • 作者指出,提供者可能选择开始替代治疗、转入临床试验、考虑再次切除,或继续当前治疗以期缓解。
  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Management of patients with glioblastoma (GBM) is complex and involves implementing standard therapies including resection, radiation therapy, and chemotherapy, as well as novel immunotherapies and targeted small-molecule inhibitors through clinical trials and precision medicine approaches. As treatments have advanced, the radiological and clinical assessment of patients with GBM has become even more challenging and nuanced. Advances in spatial resolution and both anatomical and physiological information that can be derived from MRI have greatly improved the noninvasive assessment of GBM before, during, and after therapy. Identification of pseudoprogression (PsP), defined as changes concerning for tumor progression that are, in fact, transient and related to treatment response, is critical for successful patient management. These temporary changes can produce new clinical symptoms due to mass effect and edema. Differentiating this entity from true tumor progression is a major decision point in the patient's management and prognosis. Providers may choose to start an alternative therapy, transition to a clinical trial, consider repeat resection, or continue with the current therapy in hopes of resolution. In this review, the authors describe the invasive and noninvasive techniques neurosurgeons need to be aware of to identify PsP and facilitate surgical decision-making.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Young JS, Al-Adli N, Scotford K, et al. Pseudoprogression versus true progression in glioblastoma: what neurosurgeons need to know. J Neurosurg. 2023. PMID: 36790010. doi:10.3171/2022.12.JNS222173

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。